Literature DB >> 15827204

Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.

Masanori Daibata1, Kentaro Bandobashi, Masayuki Kuroda, Shosuke Imai, Isao Miyoshi, Hirokuni Taguchi.   

Abstract

The purposeful induction of the lytic form of Epstein-Barr virus (EBV) infection combined with ganciclovir (GCV) treatment has been advocated as a novel strategy for EBV-positive B-cell lymphoma. We demonstrated that rituximab had a synergistic effect with dexamethasone on induction of the lytic EBV infection in CD20-positive lymphoma cells. Addition of GCV to the dexamethasone/rituximab-treated cells was more effective than dexamethasone/rituximab alone in killing EBV-positive lymphoma cells in vitro and in lymphoma-bearing nude mice but not in EBV-negative cells. These data suggest that induction of the lytic EBV infection with dexamethasone/rituximab in combination with GCV could be a potential virally targeted therapy for EBV-associated B-cell lymphoma.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15827204      PMCID： PMC1082780          DOI： 10.1128/JVI.79.9.5875-5879.2005

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  23 in total

1.  Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

Authors:  M A Ghetie; H Bright; E S Vitetta
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

2.  Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.

Authors:  Wen-hai Feng; Bruce Israel; Nancy Raab-Traub; Pierre Busson; Shannon C Kenney
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

3.  Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues.

Authors:  S M Moore; J S Cannon; Y C Tanhehco; F M Hamzeh; R F Ambinder
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

Review 4.  Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies.

Authors:  D V Faller; S J Mentzer; S P Perrine
Journal:  Curr Opin Oncol       Date:  2001-09       Impact factor: 3.645

5.  Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.

Authors:  E M Westphal; W Blackstock; W Feng; B Israel; S C Kenney
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

6.  Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.

Authors:  E M Westphal; A Mauser; J Swenson; M G Davis; C L Talarico; S C Kenney
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

Review 7.  Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.

Authors:  S J Mentzer; S P Perrine; D V Faller
Journal:  Transpl Infect Dis       Date:  2001-09       Impact factor: 2.228

8.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.

Authors:  D Shan; J A Ledbetter; O W Press
Journal:  Cancer Immunol Immunother       Date:  2000-03       Impact factor: 6.968

9.  Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects.

Authors:  Andrea L Rose; Barbara E Smith; David G Maloney
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 10.  Virally targeted therapies for EBV-associated malignancies.

Authors:  Bruce F Israel; Shannon C Kenney
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867
View more
  15 in total

1.  Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

Authors:  Sajal K Ghosh; Susan P Perrine; Robert M Williams; Douglas V Faller
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Bendamustine reactivates latent Epstein-Barr virus.

Authors:  Samantha G Fernandez; J J L Miranda
Journal:  Leuk Lymphoma       Date:  2015-09-15

3.  Association between Epstein-Barr virus infection and chemoresistance to docetaxel in gastric carcinoma.

Authors:  Hee Jong Shin; Do Nyun Kim; Suk Kyeong Lee
Journal:  Mol Cells       Date:  2011-05-27       Impact factor: 5.034

4.  Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.

Authors:  Mark D Sides; Gregory J Block; Bin Shan; Kyle C Esteves; Zhen Lin; Erik K Flemington; Joseph A Lasky
Journal:  Virology       Date:  2011-05-24       Impact factor: 3.616

5.  Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.

Authors:  Y Q Wang; Y Yang; H Y Zhuo; L Q Zou; Y Jiang; M Jiang
Journal:  Med Oncol       Date:  2015-01-09       Impact factor: 3.064

6.  An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.

Authors:  Shi-Dong Ma; Xianming Yu; Janet E Mertz; Jenny E Gumperz; Erik Reinheim; Ying Zhou; Weihua Tang; William J Burlingham; Margaret L Gulley; Shannon C Kenney
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

7.  LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.

Authors:  Gretchen L Bentz; Charles Randall Moss; Christopher B Whitehurst; Cary A Moody; Joseph S Pagano
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

8.  Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.

Authors:  Sajal K Ghosh; Lora W Forman; Idowu Akinsheye; Susan P Perrine; Douglas V Faller
Journal:  Blood Cells Mol Dis       Date:  2006-12-11       Impact factor: 3.039

9.  Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.

Authors:  Richard J Jones; Tawin Iempridee; Xiaobin Wang; Hans C Lee; Janet E Mertz; Shannon C Kenney; Heather C Lin; Veerabhadran Baladandayuthapani; Christopher W Dawson; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Clin Cancer Res       Date:  2016-06-13       Impact factor: 12.531

10.  Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.

Authors:  James P Dugan; Bradley M Haverkos; Lynda Villagomez; Ludmila K Martin; Mark Lustberg; John Patton; Marisa Martin; Ying Huang; Gerard Nuovo; Fengting Yan; Robert Cavaliere; Joyce Fingeroth; Shannon C Kenney; Richard F Ambinder; Gerard Lozanski; Pierluigi Porcu; Michael A Caligiuri; Robert A Baiocchi
Journal:  Clin Cancer Res       Date:  2018-04-09       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.